CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).

Foxp3+ regulatory T cells (Tregs) play a central role in maintaining immune tolerance. A reduction in the function of Tregs is a key feature of autoimmune diseases, whereas their expansion in malignant diseases leads to the suppression of host antitumor responses. We analyzed the absolute number of CD4+ and CD8(+) Tregs in the peripheral blood of 52 patients with myelodysplastic syndrome (MDS) and show a significant correlation between increased number of CD4+ Tregs and MDS subgroups with 5% or more bone marrow blasts (P < .001), high International Prognostic Scoring System (IPSS) score (P < .001), and disease progression (P < .001), whereas no correlation between CD8+ Tregs and prognostic variables was observed. The CD4+ Tregs showed a polyclonal spectratype, and the percentage of the naive subset was significantly higher in the high-risk patients compared with low-risk or healthy age-matched donors (P = .032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease.

[1]  L. Gondek,et al.  Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. , 2006, Blood.

[2]  T. Giese,et al.  In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. , 2006, Blood.

[3]  J. Schulte‐Mönting,et al.  Comparison of five prognostic scoring systems, the French–American–British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis , 2006, Annals of Hematology.

[4]  Shiang Huang,et al.  Increased population of CD4+CD25high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients , 2005, European journal of haematology.

[5]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. O'keefe,et al.  Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. , 2005, Blood.

[7]  N. Young,et al.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. , 2003, Blood.

[8]  G. Mufti.  Pathobiology, classification, and diagnosis of myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.

[9]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[10]  Z. Zemanová,et al.  A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. , 2003, Leukemia research.

[11]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[12]  J. Kochenderfer,et al.  Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. , 2002, Blood.

[13]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[14]  A. Barrett,et al.  Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. , 2001, Leukemia research.

[15]  M. Rep,et al.  Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells , 1997, The Journal of experimental medicine.

[16]  S. Roman-Roman,et al.  An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction , 1992, European journal of immunology.